STUDY SELECTION AND DATA EXTRACTION: Articles related to bisphosphonateinduced osteonecrosis of thejawwerereviewed andsummarized. Inclusion criteria required thatarticles be either case studies or case series thatwere reporting actual cases linking osteonecrosis of the jaw with bisphosphonate use. Articles that addressed sitesof osteonecrosis not involVing the jaw, teaching cases (fictitious patients), and a retrospective claims analysis paper were excluded from consideration.
DATA SYNTHESIS: Bisphosphonates haverecently beenlinked to osteonecrosis of the jaw, with the greatest incidence seen with the intravenous preparations zoledronic acid and pamidronate. Osteonecrosis refers to deathof a part of the bone, resulting in decreased bonedensity. Although the majority of occurrences have been associated with the intravenous bisphosphonates, oral bisphosphonates have also beenimplicated. Other riskfactors notedfrom reported cases include dental extraction or trauma to the jaw exposing part of the bone. It is difficult to determine an exact incidence of osteonecrosis of thejaw in the general population of patients prescribed bisphosphonates; however, theincidence in cancer patients is approximately 6-7%. CONCLUSIONS: Although discontinuation of intravenous bisphosphonates in cancer patients has been recommended, stopping oral bisphosphonates priorto dental workcannot be universally endorsed at thistime, since it is unknown whether thisis effective in reducing the riskof osteonecrosis of thejaw. Treatment of thiscondition is not well established; therefore, effortsshould be directed toward prevention. Pharmacists may further counsel patients to practice good oral hygiene and regularly followup with their dentistduringtherapy. Current evidence suggests limited surgical debridement with systemic andlocal antibiotics astreatments. mon adverse effects of intravenous bisphosphonates includefever, flu-like symptoms, and localized injectionsite reactionsP Pamidronate and zoledronic acid have also been associated with development of renal dysfunction.P Although bisphosphonates are well tolerated, cases of osteonecrosis of the jaw have recently been reportedas a rare complication associated with bisphosphonate therapy," Osteonecrosis of the jaw refers to death of the bone characterized by exposed bone in the mandible or maxilla progressing to necrosis. Signs and symptoms of the condition includeloose teeth, dental abscesses, toothaches,nonhealing extraction sockets,and bone exposure," It is also associated with severe pain, which usually develops later, once ex-Posed bone becomes infected.' Osteonecrosis of the jaw most commonly occurs following dental procedures or traumatic injury; however, spontaneous cases have been reported in the absence of a precipitating event.',9·l1 The Precise mechanismfor this adverse effect has not been fully elucidated; however, it is believed to be due in part to bisphosphonate inhibition of osteoclasts as well as the drugs' antiangiogenic properties.P'
This article summarizesthe extent of the evidence associating bisphosphonate use with osteonecrosis of the jaw, describes patient management, and provides some guidance to pharmacists on how to identify and/or prevent this Complication among patients at risk, based on the recommendations and understandingthat currently prevail in the literature.
Data Sources
A computerized search of the published literature was performedusing MEDLINE (1966-January 2007) and the International Pharmaceutical Abstracts (1970 ( -January 2007 . The search strategy combined MeSH and non-MeSH key words to describe osteonecrosis and bisphosphonates. Specific search terms included osteonecrosis, bisphosphonates, and jaw. Inclusion criteria required that articlesbe either a case study or case series reporting actual cases linkingosteonecrosis of the jaw with bisphosphonate use. Articles that addressedother sites of osteonecrosis (ie, not involving the jaw), teaching cases (fictitious patients), and a retrospective claims analysis were excluded from consideration. An effort was made to identify full articles published subsequent to abstracts reporting research in progress. Abstracts that potentially met the inclusion criteria were identified, and full articles were retrieved for further review. Reference lists for reviewed articles were cross-checked for additional relevant literature.
Cases
The literature search revealed a number of case reports and case_series as summarized in Tables 1 12 • 22 and 2. 23 • 48 In addition, 2 large case series, several retrospectivechart reviews, and survey data have contributed significantly to the body of evidence.
Cases of jaw osteonecrosis associated with bisphosphonates began to appear in the literatureas early as 2003. Initially, the reports were scattered, with a rapid increase in the number of reports in 2005 and 2006. In reviewing the reported cases, a number of trends were identified. Notably, the bisphosphonates implicated were often pamidronate or zoledronic acid, with more cases associated with zoledronic acid. Most cases involved a diagnosis of cancer (often multiple myeloma or breast cancer), and a wwwtheannalscom number of the cases also reported dental proceduresprior to the onset of osteonecrosis. There were multiple treatmentmodalities used in the cases; however,discussionof these was often incomplete.The most common treatment modalities employed includeddebridement of the infected area, treatment with antimicrobials (both local and systemic), and use of hyperbaric oxygen. Twoof the largestcase series to date are those by Marx et al. 49 Bisphosphonate-lnduced Osteonecrosis of/he Jaw dose, duration, and indication for bisphosphonate therapy; how and why the patient presented; concomitantdiseases; and presence of any precipitating event. Of the 119 patients,32 (26.8%) were receiving parnidronate, 48 (40.3%) were receiving zoledronic acid, 36 (30.2%) had received pamidronate followed by zoledronic acid, and 3 (2.5%) were receivingalendronate. The 3 patients receiving alendronate were being treated for osteoporosis, while the remaining patients were receiving therapyrelatedto a malignancy. The mean time from first drug exposure until onset of exposed bone was documented as 14.3 months for pamidronate, 12.1 months for pamidronate followed by zoledronic acid, 9.4 months for zoledronic acid alone, and 3 years for alendronate. The majority (69.9%) of patients presented with exposed bone and pain. All cases involved the mandible or maxilla. Osteonecrosis was reported to be spontaneous in 25.2% of cases; it was precipitated by tooth removal in 37.8% of cases and discovered with preexisting periodontal disease or surgery in 39.8% of cases, placement of a dental implant in 3.4% of cases, and apicoectomy (excision of the apical portion of a tooth) in 0.8% of cases,"
The authors recommended referral to an experienced dentist for all patients prescribed a bisphosphonate and referral to an oral surgeon when exposed bone was identified. Other recommendations included debridement for refractory cases and antibiotic therapy. The recommended antibiotic regimen was long-term penicillin V-K 500 mg 4 times daily with local 1.2% chlorhexidine rinse; metronidazole was added for refractory cases. This antibiotic regimen was used in 97 of the cases (6 pts. died of cancer); in 82 (90.1 %) of the remaining 91 patients, the antibiotic treatment resulted in freedom from pain and further wound irrigations. Nine patients required alterations in the antibiotic regimen, including 3 who required hospitalization and intravenous antibiotics. The authors concluded that risks for bisphosphonate-induced exposed bone were the cumulative bisphosphonate dose, duration of therapy, invasive dental procedures, and preexisting dental disease. They also stated that, although only 3 patients in their series had received oral alendronate, caution should be exercised in patients receiving oral bisphosphonates due to their long prolonged effect in the bone and the likelihood of longterm use. 49 This case series summarized the characteristics for 119 patients; however, there were no controls or statistical analyses. Also, the recommendation for long-term antibiotics is of concern, considering the risk for antibiotic resistance. Local therapy with short-term antibiotics may be equally effective.
Ruggiero et al. 50 identified 63 patients with osteonecrosis of the jaw at their oral and maxillofacial surgery center. Of those patients, 7 (11%) had no history of cancer and were receiving oral bisphosphonates for the treatment of osteoporosis. Nine (14%) of the patients did not have a dental procedure prior to development of necrosis. The authors reported that, in 3 years, only 4 patients not receiving bisphosphonates had presented with similar osteonecrosis of the jaw. Minor debridement procedures were attempted in all patients, but most required more radical surgical procedures. Two patients also received hyperbaric oxygen therapy and then required further surgical management. The authors recommended dental evaluations for all patients beginning bisphosphonate therapy. Other recommendations included surgical management for symptomatic patients and local irrigations with antibiotic therapy for those with limited areas of affected bone. Type and duration of antibiotic therapy were not specified. Similar to the case series above, this report also lacked controls and statistical analysis.
Several retrospective reviews and case series have been identified that may be useful in determining an incidence of the disease either in the population of patients with cancer or in the population of patients receiving intravenous bisphosphonates.
A review was conducted of patients with multiple myeloma who underwent a dental assessment," Twentytwo cases of jaw osteonecrosis were identified; 11 from a database of 340 patients (a 3% incidence among myeloma patients in the database) and 11 who were referred to the authors. All patients with jaw osteonecrosis had received intravenous bisphosphonate therapy with either parnidronate, zoledronic acid, or both agents (at different periods of time), and most presented with jaw pain. Twelve (55%) of 22 cases had documentation of a prior dental procedure. Upon identification of jaw osteonecrosis, bisphosphonate therapy was discontinued in all patients. Fourteen patients were treated with debridement and bone removal; 8 of these patients experienced serious complications including infection. Six patients were managed initially with antibiotic therapy and bone removal only when deemed necessary. Three of those patients underwent further treatment due to poor healing.
The risk factors for bisphosphonate-induced osteonecrosis of the jaw identified in this review included dental extraction (OR 0.11; 95% CI 0.02 to 0.57), therapy with pamidronate followed by zoledronic acid (OR 0.16; 95% CI 0.04 to 0.63), age (9% increase in risk with each decade; OR 1.09; 95% CI 1.01 to 1.17), and time from myeloma diagnosis (57% increase in risk per year of disease; OR 1.57; 95% CI 1.13 to 2.17). 9 Another review evaluated 252 charts of cancer patients receiving hisphosphonates." Seventeen (6.7%) patients were diagnosed with jaw osteonecrosis; all of those patients had received zoledronic acid. Seven received zoledronic acid without other bisphosphonates, 9 received pamidronate in addition to zoledronic acid, and 1 received ibandronate with zoledronic acid. Dental extractions had been performed in 13 of the patients, and 2 patients had dentures. All patients were treated with antibiotics (only 1 had sustained relief), debridement was performed only when there was risk to surrounding tissues, and 1 patient underwent hyperbaric oxygen treatment that was unsuccessful.
Risk factors identified included time of exposure (mean duration 39.3 mo among patients developing osteonecrosis and 19 mo among those with no osteonecrosis; p = 0.001) and dental procedures (76% had a dental procedure within the last year and another 12% had dentures),"
Theseauthors recently publisheda second report from theirdatabase." This report included only patients with rnUltiple myeloma. A 7.4% (15/202 pts.) incidence of jaw Osteonecrosis was identified. Similar to findings of their initial report,zoledronic acid was the most frequently im-Plicated bisphosphonate, 67% of the patients had recent dental procedures, and duration of exposure was a signifi-Cant riskfactor.
In a report similar to the database reviews above, Guarino et al,53 identified 6 (6%) cases of jaw osteonecrosis among 101 cancerpatients receiving intravenous bisphos-Phonates. As in otherreports, most patients werereceiving zoledronic acid(n =5;with 1 pt. receiving pamidronate and another receiving bothagents). Manypatients (number not stated) had significant dentalproblems. Most were treated With systemic antibiotics andlimited surgical debridement.
In another article, 9 cases of osteonecrosis of the jaw Were identified among 194 patients receiving zoledronic acid (4.6% incidence)," Although very few data regarding thepatients weregiven,6 patients had usedpamidronate in the past. The median durationof zoledronic acid use was 18 months.
Tosi et a1. 55 conducted a retrospective chart review of 259consecutive patients with multiple myelomato determine an incidence of osteonecrosis of thejaw.The authors alsoattempted to determine whetherconcomitant therapy for myelomacontributed to development of osteonecrosis of the jaw. Therapy consisted of thalidomide, high-dose dexamethasone, double autologous transplant with mel-Phan, and zoledronic acid 4 mg every 28 days (length of therapy at discretion of physician). A total of9 (3.47%) of 259patients developed the condition. The median duration of zoledronic acid therapy was 10 months (range4-35) in thetotalpopulation compared with 17months in the group that developed osteonecrosisof the jaw (p < 0.0 I). Four patients responded to minimally invasive therapy (not Specified), 3 experienced partial improvement, and 2 had no improvement. Data were not reported for presence of Confounding variables; however, the authors stated that noneof the concurrenttherapies were importantrisk factors for development of osteonecrosis of thejaw.
Finally, jaw osteonecrosis was identified in 34 patients amonga cohort of 4025 patients (4019 from a pharmacy database).56 Using the database to calculate frequency of jaw osteonecrosis, the authorsdetermineda frequency of 1.2% among patients with breastcancer and 3.1% among those with multiple myeloma.
The International Myeloma Foundation conducted a survey in an attempt to define risk factors for development of osteonecrosis of thejaw," Therewere 1203 respondents (904 with multiple myeloma, 299 with breast cancer). A total of 75 patients reported osteonecrosisof the jaw (62 With myeloma,13 with breast cancer)and another77 had Suspicious findings. The occurrence of osteonecrosis was Bisphosphonate-Induced Osteonecrosis of the Jaw morecommon in patients receiving zoledronic acid than in those receiving pamidronate (10/211 vs 4/413; P =0.002).
Dental risk factors were present in 81% of the multiple myeloma patients and 69% of the breast cancer patients with osteonecrosis of the jaw. Therapies such as corticosteroids or thalidomide did not contribute additional risk.
Discussion
Basedon the available literature, it appears that bisphosphonates are associated with an increased risk of osteonecrosis of the jaw. Although the exact mechanism is unknown, the effects of bisphosphonates on osteoclast activity likely playa role; however, the antiangiogenesis that results from bisphosphonate administration may also be involved.9~~9.s8
Migliorati et al, 39 proposed that, becausethe bisphosphonates inhibit osteoclast activity, thereis a reduction in bonemulticellular unitsincluding bloodvessels, osteoclasts, and osteoblasts. This results in decreasedblood flow and boneremodeling impairment. Infection also likely contributes to the process sincethe mouthcontains multiplebacteria. There is lessevidence to support angiogenesis inhibition as an initial mechanism; however, pamidronate and zoledronic acidhavebeenshown to havethese properties in animal models,"
It appears from the available literature that the intravenousagents,especially zoledronic acid, are more likely to predispose patients to osteonecrosis of the jaw. The exact reason for thisremains unknown. Zoledronic acidis the most potent of the bisphosphonates, which may be a contributing factor. In addition,the intravenous drugs, unlike the oral bisphosphonates, are often used in patients with other risk factors for osteonecrosis of the jaw including concomitant malignancy, corticosteroid use, and radiation.
In addition to bisphosphonate use, there appear to be several other factors involved in the development of osteonecrosis of the jaw. Most patients had prior dental procedures; however, there are cases of spontaneous occurrence. There alsoappears to besome evidence fora dose-response relationship. In the survey conducted by the International Myeloma Foundation, the mean time to osteonecrosis onset was 6 years in patients receiving pamidronate and 18months in patients receiving zoledronic acid." Other reports suggestshortermeanonsettimes,but fewreport onset at treatment duration of lessthan1 year.
The reported treatment of osteonecrosis of the jaw is quite variable, and no consensus has been established.A number of the reported cases have had one or more treatments such as local debridement, surgeryincludingbone resection, systemic antibiotics, antiseptic mouthrinses, and hyperbaric oxygen. A recurrent theme throughout the literatureis the fact that hyperbaric oxygen,although effective in osteoradionecrosis, has been ineffective in most bisphosphonate-induced cases. Bisphosphonate discontinua-
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The Annals of Pharmacotherapy • 2007February, Volume 41 • 281 tion is also controversial. Although many patients have discontinued therapy, thesedrugsremainin bone for an extendedtime period,and the clinical benefitof therapy may exceedthe risksof continuation. Limitedtreatmentof the bony area is now recommended over invasive procedures, whichhavebeen shownto increase the area of necrosis. Many reports and recent recommendations suggest minimizing sharp edges of the bone to avoid soft tissue trauma. Many case reports mentioned use of an antisepticmouthwash such as chlorhexidine, and this practiceis currentlyrecommended. The use of systemic antibiotics has been reported; however, the exact agent was usually not specified (penicillin was the most commondrug reported whenspecified). The recommendationsfrom the American Academy of Oral Medicine are to culturewhen possible and, whenindicated, treat with penicillin,amoxicillin, and/orclindamycin,"
Due to the lack of definitive treatment of jaw osteonecrosis, prevention should be a priority.This can be accomplished mainly throughimplementation of a thorough dental examination prior to initiation of intravenous bisphosphonate therapy. This assessment of the patient may lead to identification of existing dental complications, which may thenbe treated priorto initiation of the bisphosphonate. There is less urgency for patients starting or receiving oral bisphosphonates; however, these patients should be seen by a dentist within 3 months of starting therapy. This allows for treatmentof dental complications beforethe patientis exposedto bisphosphonates for a prolonged period of time when the risk for osteonecrosis of the jaw increases. Patients shouldalso be counseled on the importance of dental hygiene and regularfollow-up with a dentistduringtheirtreatment withbisphosphonates.
In responseto recent literaturelinkingbisphosphonates to osteonecrosisof the jaw, the Mayo Clinic has issued a consensus statement regarding recommendations for use of these drugs in patients with multiple myeloma." Key points from this documentinclude limitingthe use of bisphosphonatesto 2 years when possible (if the patient has achieveda response), suggesting pamidronate as first-line therapy sincethe incidence of osteonecrosis of the jaw appearsto be morecommonwith zoledronic acid,and implementing preventive measures. Patients are encouraged to undergodental examinationprior to initiationof therapy; this recommendation is similar to that of the American Academy of Oral Medicine.Of note, the consensus group suggeststhat patients with multiple myeloma who are already receiving bisphosphonates and require dental work discontinue the drug at least 1 monthbeforethe procedure. Bisphosphonates may be reinitiated after the wound has healed. The MayoClinicpublication is basedlargely on the opinion of the consensus group ratherthanon well-designed clinical trials, dueto the nature of available evidence.
The incidence of bisphosphonate-induced osteonecrosis of the jaw should still be considered rare. It is difficultto determine an incidence in the general population of patients prescribed bisphosphonates; however, database reviews of those with cancer who are receiving bisphosphonates suggestthe incidence in that population is around 6% or 7%. 51, 53 Postmarketing surveillance will continue to capturereports of thisadverse event. The failure of clinical trials to identify rare adverse eventsis not uncommon; long-term studiesof the intravenous bisphosphonates have generally extendedonly to approximately 2 years, which may have been too short to identify this event. On the other hand, a long-term (10 y) studywith alendronate use in 247 women with osteoporosis didnotreport osteonecrosis of thejaw,"
Summary
Osteonecrosis of the jaw appearsto be a class effectassociated with bisphosphonates, although the reported incidence is significantly higher with the intravenous preparations zoledronic acid and pamidronate. The risk appears to be minimal for patients receiving oral bisphosphonates-Treatmentof this condition is not well established; therefore, efforts should be directed toward prevention. Pharmacists are in a unique position to educate patients about this adverse event and suggest preventive strategies such as completing major dental work prior to starting a bisphosphonate. Pharmacists may further counselpatients to practice good oral hygiene and regularly follow up with their dentist during therapy;these points can be discussed in counseling sessions when prescriptions are picked up at outpatient pharmacies. On a global level,pharmacists may be able to participate in discussions and development of futureguidance on this topic.
Although discontinuation of intravenous bisphosphonates in cancer patients has been recommended, stopping oral bisphosphonatesprior to dental work cannot be universally endorsedat this time, since it is unknown whether this is effective in reducing the risk. SELECCl6N DEFSl'UDIOSY EXTRACCl6NDE DATOS: Artlculos relacionados a osteonecrosis de la mandfbula inducidapoebisfosfonatos fueron revisados y resumidos. Criteriosde inclusi6n requerfan que los artfculos fueranestudio de casos0 seriede casos, reportando casos ligando osteonecrosis de la mandfbula al uso de bisfosfonatos. Artlculos exponiendo otros sitiosde osteonecrosis, no incluyendo la mandfbula, caso de enseiianza (pacientes ticticios),y artfculos de reclamopor aruUisis retrospectivo fueronexcluidos para consideraci6n. sfNTEslS: Bisfosfonatos han sido ligadosrecientemente a osteonecrosis de la mandfbula, Osteonecrosis se retierea la muertede parte del hueso resultando en disminuci6n de Iadensidad6sea. La mayorfade las ocurrencias han sido asociadas al usode bisfosfonatos intravenosos; sin embargo,tambienhan sido irnplicados los bisfosfonatos orales.Otros faetoresde riesgoencontrados en los casos reportados incluyen exttaccionesdentales0 traumaa la mandfbula exponiendo partedel hueso.La evidenciarecientesugiereremoci6nquin1rgica limitadadel tejidocon antibi6ticos sistemicos 0 localescomo tratamiento. CONCLUSIONES: Osteonecrosis de la quijadaaparentaser un efectode claseasociadoa los bisfosfonatos, aunque la incidencia es signiticativamente mas alta con preparaciones intravenosas de acido zoledr6nico y pamidronato. Es diffcil determinarla incidencia exactaen la poblaci6ngeneralde pacientescon bisfosfonatos; sin embargo,la incidencia en pacientes de canceres aproximadamente 6 0 7%. EI tratamiento de esta condici6nno estabien establecido y por 10 tanto, los esfuerzos deben dirigirsea la prevenci6n. Los farmaceuticos deben aconsejara los pacientes a practicarbuena higieneoral y visitas regularesde seguimiento con su dentistadurantela terapia.Aunque la descontinuaci6n de bisfosfonatos intravenosos en pacientes de cancer ha sido recomendada, detener los bisfosfonatos orales antesde un trabajo dental no puede ser endosadouniversalmente en este momento,ya que se desconocesi esto es 0 no efectivoreduciendoel riesgo. SYN11IEsEDESDONNEES: Les biphosphonates ont recemment ete mis en lien avec l'osteoneerose de rnachoire. L'osteonecrose consisteen une disparition d'une partiede l'os, ce qui conduitaune diminution de densite osseuse.La majorite des survenues ont ete associees aux biphosphonates intraveineux; cependant, les biphosphonates orauxont aussiete impliques. Les autresfacteursde risquesressortant des cas rapportes comprennent les extractions dentaires ou les traumatismes de machoiremettantanu une partiede l'os, Les elementsactuellement etablispreconisentde procederaun debridement chirurgical lirnite, associeades traitements antibiotiques systemiques et locaux. CONCLUSIONS: L'osteonecrose de machoire apparait etre un effetde classedes biphosphonates, rnalgre une incidencesigniticativement plus elevee avec les preparations intraveineuses d'acide zoledronique et de parnidronate. II est difficilede determinerI'incidenceexactedans la population generale des patientssous biphosphonates; cependant, I'incidencechez Iespatientscancereux est d'environ 6 a7%. Le traitementde ce problemen'est pasbien etabliet, de ce fait, les efforts devraientportersur la prevention. Les pharmaciens peuventconseiller aux patientsde suivreune bonnehygienebuccaleet consulter regulierement leur dentistedurantleur therapie, Bien que I'interruption des biphosphonates intraveineux ait ete recommandee chez les patients cancereux.l'arret des biphosphonates oraux dans l'attente d'effectuer des soinsdentairesne peut pas etre systematiquement justifiepour Ie moment,car on ne sait passi cela est efficaceou non pourreduire Ie risque.
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